| 000 | 01640 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514024127.0 | ||
| 264 | 0 | _c20020308 | |
| 008 | 200203s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/s00280-001-0389-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFyfe, D | |
| 245 | 0 | 0 |
_aA study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cJan 2002 |
||
| 300 |
_a1-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAmsacrine _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRaynaud, F | |
| 700 | 1 | _aLangley, R E | |
| 700 | 1 | _aNewell, D R | |
| 700 | 1 | _aHalbert, G | |
| 700 | 1 | _aGardner, C | |
| 700 | 1 | _aClayton, K | |
| 700 | 1 | _aWoll, P J | |
| 700 | 1 | _aJudson, I | |
| 700 | 1 | _aCarmichael, J | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 49 _gno. 1 _gp. 1-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-001-0389-z _zAvailable from publisher's website |
| 999 |
_c11763992 _d11763992 |
||